This article is intended for primary care clinicians, geriatricians, endocrinologists, and other specialists who care for patients at risk for insulin resistance.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/07. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
CME Released: 8/15/2008
Valid for credit through: 8/15/2009
processing....
August 15, 2008 — Vitamin K supplementation for 36 months at doses that could be achieved through dietary intake may reduce progression of insulin resistance in older men, according to the results of a study reported in the August 12 Online First issue of Diabetes Care.
"Vitamin K has a potentially beneficial role on insulin resistance, but evidence is limited in humans," write Makiko Yoshida, PhD, from the Jean Mayer US Department of Agriculture Human Nutrition Research Center at Tufts University in Boston, Massachusetts, and colleagues. "We tested the hypothesis that vitamin K supplementation for 36 months will improve insulin resistance in older men and women."
This was an ancillary study of a 36-month, randomized, double-blind, controlled clinical trial in which the primary objective was to determine the effect of supplementation with 500 μg/day of phylloquinone (vitamin K) on bone loss. The study sample consisted of 355 nondiabetic adults aged 60 to 80 years; 60% were women. The main endpoint was insulin resistance, measured by the homeostasis model (HOMA-IR) evaluated at 36 months, and secondary endpoints were fasting plasma insulin and glucose.
The affect on the HOMA-IR of 36-month vitamin K supplementation was different in men and in women (sex-by-treatment interaction: P = .02). Compared with men in the control group, men in the supplement group had statistically significantly lower HOMA-IR at 36 months (P = .01), after adjustment for baseline HOMA-IR, body mass index (BMI), and body weight change. Women in the 2 intervention groups did not differ significantly in HOMA-IR or in other outcome measures.
"Vitamin K supplementation for 36 months at doses attainable in the diet may reduce progression of insulin resistance in older men," the study authors write. "There was an inverse association between plasma phylloquinone concentrations and BMI in the women suggestive of an impaired response to vitamin K supplementation."
Limitations of this study include analyses of data obtained from a study designed to determine the effect of vitamin K supplementation on changes in bone mineral density and vascular calcification in older men and women; possible lack of generalizability to the overall population; measures presented not necessarily obtained by optimal techniques; limited statistical power to detect differences in HOMA-IR in response to vitamin K supplementation; and predominantly Caucasian sample.
"In summary, 36 months of vitamin K supplementation had a beneficial effect on insulin resistance in older men, but not older women," the study authors conclude. "As the parent study was not designed to test this hypothesis, these findings need to be replicated in a study designed specifically to test the hypothesis that vitamin K plays a protective role in insulin resistance in older adults."
Hermes Arzenemittel GMBH, Munich, Germany, donated the supplements used for this study. The US Department of Agriculture and American Heart Association supported this study. The Ministry of Education, Culture, Sports, and Technology in Japan supported one author and the American Diabetes Association supported another author.
Diabetes Care. Published online August 12, 2008.
Limited evidence from human and animal studies suggest a role for vitamin K supplementation in improving insulin sensitivity and glycemic status, but this effect has not been studied in a randomized trial of men and women without diabetes.
This is a study conducted within another placebo-controlled randomized trial to examine the effect of vitamin K supplementation among men and women without diabetes on insulin resistance as measured by the HOMA-IR. The main study examined the role of vitamin K supplementation on fractures in the elderly.